Rifaximin – ein nicht resorbierbares Antibiotikum mit vielfältigen Anwendungsmöglichkeiten in der Gastroenterologie

T. Rabenstein; M. F. Fromm; O. Zolk

doi:10.1055/s-0029-1245705

Zeitschrift für Gastroenterologie, Inhaltsverzeichnis

Z Gastroenterol 2011; 49(2): 211-224
DOI: 10.1055/s-0029-1245705

Übersicht

Rifaximin – ein nicht resorbierbares Antibiotikum mit vielfältigen Anwendungsmöglichkeiten in der Gastroenterologie

Rifaximin – A Non-Resorbable Antibiotic with Many Indications in GastroenterologyT. Rabenstein¹ , M. F. Fromm² , O. Zolk²

¹Innere Medizin und Gastroenterologie, Diakonissen-Stiftungs-Krankenhaus Speyer
²Friedrich-Alexander-Universität Erlangen-Nürnberg, Institut für Experimentelle und Klinische Pharmakologie und Toxikologie, Lehrstuhl für Klinische Pharmakologie und Klinische Toxikologie

Abstract

Zusammenfassung

Seit 2 Jahren ist in Deutschland Rifaximin als darmselektives Breitbandantibiotikum zur Behandlung der durch nicht invasive enteropathogene Bakterien verursachten Reisediarrhö verfügbar. Aufgrund der guten Verträglichkeit und der hohen Wirksamkeit gegen darmpathogene Erreger wird ein hohes Zukunftspotenzial dieses seit mehr als 25 Jahren bekannten Arzneistoffs v. a. in weiteren Indikationsgebieten gesehen, die Gegenstand aktueller klinischer Untersuchungen sind. Dazu zählt die Behandlung der Divertikelerkrankung, der Clostridium-difficile-assoziierten Diarrhö und der pseudomembranösen Kolitis, der bakteriellen Fehlbesiedlung des Dünndarms, des Reizdarmsyndroms sowie der hepatischen Enzephalopathie. Diese Übersicht zeigt mögliche Einsatzgebiete in der Gastroenterologie auf und beurteilt kritisch den Stellenwert von Rifaximin in der Behandlung dieser Erkrankungen anhand neuester Daten.

Abstract

Rifaximin, a non-resorbable broadband antibiotic, was approved in Germany 2 years ago for the treatment of traveller’s diarrhoea caused by non-invasive enteropathogens. On account of the very good tolerance and the high efficacy against almost all enteropathogens this pharmaceutical, which has been available for 25 years, bears a high potential in many other indications which are currently under clinical investigations, including: symptomatic uncomplicated diverticular disease, Clostridium difficile-associated diarrhoea and pseudomembranous colitis, small bowel intestinal bacterial overgrowth, irritable bowel syndrome and hepathic encephalopathy. The present overview demonstrates potential indications in the field of gastroenterology and critically reviews the significance of rifiximin in the treatment of these diseases based on the latest clinica data.

Schlüsselwörter

bakterielle Fehlbesiedlung - Divertikulose - infektiöse Kolitis - Laktoseintoleranz - pseudomembranöse Kolitis - Colon irritabile

Key words

small bowel intestinal bacterial overgrowth - diverticular disease - infectious colitis - lactose intolerance - pseudomembranous colitis - irritable bowel syndrome

Volltext

Referenzen

Literatur

1 Jiang Z D, Ke S, Palazzini E et al. In vitro activity and fecal concentration of rifaximin after oral administration. Antimicrob Agents Chemother. 2000; 44 2205-2206
2 Descombe J J, Dubourg D, Picard M et al. Pharmacokinetic study of rifaximin after oral administration in healthy volunteers. Int J Clin Pharmacol Res. 1994; 14 51-56
3 Gionchetti P, Rizzello F, Ferrieri A et al. Rifaximin in patients with moderate or severe ulcerative colitis refractory to steroid-treatment: a double-blind, placebo-controlled trial. Dig Dis Sci. 1999; 44 1220-1221
4 Rizzello F, Gionchetti P, Venturi A et al. Rifaximin systemic absorption in patients with ulcerative colitis. Eur J Clin Pharmacol. 1998; 54 91-93
5 Gomi H, Jiang Z D, Adachi J A et al. In vitro antimicrobial susceptibility testing of bacterial enteropathogens causing traveler’s diarrhea in four geographic regions. Antimicrob Agents Chemother. 2001; 45 212-216
6 Ruiz J, Mensa L, O’Callaghan C et al. In vitro antimicrobial activity of rifaximin against enteropathogens causing traveler’s diarrhea. Diagn Microbiol Infect Dis. 2007; 59 473-475
7 Steffen R, Sack D A, Riopel L et al. Therapy of travelers’ diarrhea with rifaximin on various continents. Am J Gastroenterol. 2003; 98 1073-1078
8 Taylor D N, Bourgeois A L, Ericsson C D et al. A randomized, double-blind, multicenter study of rifaximin compared with placebo and with ciprofloxacin in the treatment of travelers’ diarrhea. Am J Trop Med Hyg. 2006; 74 1060-1066
9 O’Connor J R, Galang M A, Sambol S P et al. Rifampin and rifaximin resistance in clinical isolates of Clostridium difficile. Antimicrob Agents Chemother. 2008; 52 2813-2817
10 De-Leo C, Eftimiadi C, Schito G C. Rapid disappearance from the intestinal tract of bacteria resistant to rifaximin. Drugs Exp Clin Res. 1986; 12 979-981
11 Brigidi P, Swennen E, Rizzello F et al. Effects of rifaximin administration on the intestinal microbiota in patients with ulcerative colitis. J Chemother. 2002; 14 290-295
12 Dupont H L, Jiang Z D. Influence of rifaximin treatment on the susceptibility of intestinal Gram-negative flora and enterococci. Clin Microbiol Infect. 2004; 10 1009-1011
13 Fumi A L, Trexler K. Rifaximin treatment for symptoms of irritable bowel syndrome. Ann Pharmacother. 2008; 42 408-412
14 Bertoli D, Borelli G. Teratogenic action of Rifaximin in the rat and rabbit and its effect on perinatal development in the rat. Boll Soc Ital Biol Sper. 1984; 60 1079-1085
15 Borelli G, Bertoli D. Acute, subacute, chronic toxicity and mutagenicity studies of rifaximin (L/ 105) in rats. Chemioterapia. 1986; 5 263-267
16 Ma X, Shah Y M, Guo G L et al. Rifaximin is a gut-specific human pregnane X receptor activator. J Pharmacol Exp Ther. 2007; 322 391-398
17 Trapnell C B, Connolly M, Pentikis H et al. Absence of effect of oral rifaximin on the pharmacokinetics of ethinyl estradiol/norgestimate in healthy females. Ann Pharmacother. 2007; 41 222-228
18 Pentikis H S, Connolly M, Trapnell C B et al. The effect of multiple-dose, oral rifaximin on the pharmacokinetics of intravenous and oral midazolam in healthy volunteers. Pharmacotherapy. 2007; 27 1361-1369
19 Dupont H L, Jiang Z D, Belkind-Gerson J et al. Treatment of travelers’ diarrhea: randomized trial comparing rifaximin, rifaximin plus loperamide, and loperamide alone. Clin Gastroenterol Hepatol. 2007; 5 451-456
20 Dupont H L, Ericsson C D. Prevention and treatment of traveler’s diarrhea. N Engl J Med. 1993; 328 1821-1827
21 Ericsson C D, Dupont H L. Rifaximin in the treatment of infectious diarrhea. Chemotherapy. 2005; 51 /Suppl 1) 73-80
22 Gillis J C, Brogden R N. Rifaximin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential in conditions mediated by gastrointestinal bacteria. Drugs. 1995; 49 467-484
23 Ruiz J, Mensa L, Pons M J et al. Development of Escherichia coli rifaximin-resistant mutants: frequency of selection and stability. J Antimicrob Chemother. 2008; 61 1016-1019
24 Vitali B, Turroni S, Serina S et al. Molecular and phenotypic traits of in-vitro-selected mutants of Bifidobacterium resistant to rifaximin. Int J Antimicrob Agents. 2008; 31 555-560
25 Dupont H L, Ericsson C D, Mathewson J J et al. Rifaximin: a nonabsorbed antimicrobial in the therapy of travelers’ diarrhea. Digestion. 1998; 59 708-714
26 Dupont H L, Jiang Z D, Ericsson C D et al. Rifaximin versus ciprofloxacin for the treatment of traveler’s diarrhea: a randomized, double-blind clinical trial. Clin Infect Dis. 2001; 33 1807-1815
27 Dupont H L, Haake R, Taylor D N et al. Rifaximin treatment of pathogen-negative travelers’ diarrhea. J Travel Med. 2007; 14 16-19
28 Dupont H L, Jiang Z D, Okhuysen P C et al. A randomized, double-blind, placebo-controlled trial of rifaximin to prevent travelers’ diarrhea. Ann Intern Med. 2005; 142 805-812
29 Taylor D N, McKenzie R, Durbin A et al. Rifaximin, a nonabsorbed oral antibiotic, prevents shigellosis after experimental challenge. Clin Infect Dis. 2006; 42 1283-1288
30 Taylor D N, McKenzie R, Durbin A et al. Systemic pharmacokinetics of rifaximin in volunteers with shigellosis. Antimicrob Agents Chemother. 2008; 52 1179-1181
31 Jiang Z D, Dupont H L, La R M et al. In vitro susceptibility of Clostridium difficile to rifaximin and rifampin in 359 consecutive isolates at a university hospital in Houston, Texas. J Clin Pathol. 2010; 63 355-358
32 Dupont H L. Clinical practice. Bacterial diarrhea. N Engl J Med. 2009; 361 1560-1569
33 Dupont H L. Systematic review: the epidemiology and clinical features of travellers’ diarrhoea. Aliment Pharmacol Ther. 2009; 30 187-196
34 Amenta M, le Nogare E R, Colomba C et al. Intestinal protozoa in HIV-infected patients: effect of rifaximin in Cryptosporidium parvum and Blastocystis hominis infections. J Chemother. 1999; 11 391-395
35 Schneider T, Eckmanns T, Ignatius R et al. Clostridium-difficile-assoziierte Diarrhö: Ein zunehmendes klinisches Problem durch neue hochvirulente Erreger. Dtsch Arztebl. 2007; 104 1588-1594
36 Eichel-Streiber C, Braun V. Das difficile Clostridium. J Lab Med. 2008; 32 219-234
37 Gerding D N, Muto C A, Owens R C et al. Treatment of Clostridium difficile infection. Clin Infect Dis. 2008; 46 (Suppl 1) S32-S42
38 Kokkotou E, Moss A C, Michos A et al. Comparative efficacies of rifaximin and vancomycin for treatment of Clostridium difficile-associated diarrhea and prevention of disease recurrence in hamsters. Antimicrob Agents Chemother. 2008; 52 1121-1126
39 Surawicz C M. Antibiotic-associated diarrhea and pseudomembranous colitis: are they less common with poorly absorbed antimicrobials?. Chemotherapy. 2005; 51 (Suppl 1) 81-89
40 Garey K W, Salazar M, Shah D et al. Rifamycin antibiotics for treatment of Clostridium difficile-associated diarrhea. Ann Pharmacother. 2008; 42 827-835
41 Boero M, Berti E, Morgando A et al. Treatment for colitis caused by Clostridium difficile: results of a randomized, open-label study of rifaximin vs. vancomycin. Microbiologia Medica. 1990; 5 74-77
42 Johnson S, Schriever C, Galang M et al. Interruption of recurrent Clostridium difficile-associated diarrhea episodes by serial therapy with vancomycin and rifaximin. Clin Infect Dis. 2007; 44 846-848
43 Garey K W, Jiang Z D, Bellard A et al. Rifaximin in Treatment of Recurrent Clostridium difficile-associated Diarrhea: An Uncontrolled Pilot Study. J Clin Gastroenterol. 2009; 43 91-93
44 Bascu P P, Diani A, Rayapudi K et al. Rifaximin salvage therapy for metranizole-resistant clostridium difficile infection – a prospective trial [Abstract]. Gastroenterology. 2009; 104 A1099
45 Curry S R, Marsh J W, Shutt K A et al. High frequency of rifampin resistance identified in an epidemic Clostridium difficile clone from a large teaching hospital. Clin Infect Dis. 2009; 48 425-429
46 Wettstein M, Kircheis G, Häussinger D. Hepatische Enzephalopathie – Diagnostik. Dtsch Med Wochenschr. 2003; 128 2654-2657
47 Als-Nielsen B, Gluud L L, Gluud C. Non-absorbable disaccharides for hepatic encephalopathy: systematic review of randomised trials. BMJ. 2004; 328 1046
48 Bucci L, Palmieri G C. Double-blind, double-dummy comparison between treatment with rifaximin and lactulose in patients with medium to severe degree hepatic encephalopathy. Curr Med Res Opin. 1993; 13 109-118
49 De Marco F, Santamaria Amato P, D’Arienzo A. Rifaximin in collateral treatment of portal-systemic encephalopathy: A preliminary report. Curr Ther Res. 1984; 36 668-674
50 DiPiazza S, Gabriella F M, Valenza L M et al. Rifaximine versus neomycin in the treatment of portosystemic encephalopathy. Ital J Gastroenterol. 1991; 23 403-407
51 Fera G, Agostinacchio F, Nigro M et al. Rifaximin in the treatment of hepatic encophalopathy. Eur J Res. 1993; 4 109-118
52 Festi D, Mazzella G, Parini P et al. Treatment of hepatic encephalopathy with non-absorbable antibiotics. Ital J Gastroenterol. 1992; 24 14-16
53 Loguercio C, Federico A, De G et al. Cyclic treatment of chronic hepatic encephalopathy with rifaximin. Results of a double-blind clinical study. Minerva Gastroenterol Dietol. 2003; 49 53-62
54 Mas A, Rodes J, Sunyer L et al. Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trial. J Hepatol. 2003; 38 51-58
55 Massa M D, Vallerino M D, Dodero M D. Treatment of hepatic encephalopathy with rifaximin: Double-blind, double-dummy study versus lactulose. Eur J Clin Res. 1993; 4 7-18
56 Miglio F, Valpiani D, Rossellini S R et al. Rifaximin, a non-absorbable rifamycin, for the treatment of hepatic encephalopathy. A double-blind, randomised trial. Curr Med Res Opin. 1997; 13 593-601
57 Parini P, Cipolla A, Ronchi M et al. Effect of rifaximin in the treatment of portal-systemic encephalopathy. Curr Ther Res. 1992; 52 34-39
58 Pedretti G, Calzetti C, Missale G et al. Rifaximin versus neomycin on hyperammoniemia in chronic portal systemic encephalopathy of cirrhotics. A double-blind, randomized trial. Ital J Gastroenterol. 1991; 23 175-178
59 Testa R, Eftimiadi C, Sukkar G S et al. A non-absorbable rifamycin for treatment of hepatic encephalopathy. Drugs Exp Clin Res. 1985; 11 387-392
60 Williams R, James O F, Warnes T W et al. Evaluation of the efficacy and safety of rifaximin in the treatment of hepatic encephalopathy: a double-blind, randomized, dose-finding multi-centre study. Eur J Gastroenterol Hepatol. 2000; 12 203-208
61 Zeneroli M L, Avallone R, Corsi L et al. Management of hepatic encephalopathy: role of rifaximin. Chemotherapy. 2005; 51 (Suppl 1) 90-95
62 Paik Y H, Lee K S, Han K H et al. Comparison of rifaximin and lactulose for the treatment of hepatic encephalopathy: a prospective randomized study. Yonsei Med J. 2005; 46 399-407
63 Bass N M, Mullen K D, Sanyal A et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med. 2010; 362 1071-1081
64 Neff G W, Kemmer N, Zacharias V C et al. Analysis of hospitalizations comparing rifaximin versus lactulose in the management of hepatic encephalopathy. Transplant Proc. 2006; 38 3552-3555
65 Vlachogiannakos J, Saveriadis A S, Viazis N et al. Intestinal decontamination improves liver haemodynamics in patients with alcohol-related decompensated cirrhosis. Aliment Pharmacol Ther. 2009; 29 992-999
66 Attar A, Flourie B, Rambaud J C et al. Antibiotic efficacy in small intestinal bacterial overgrowth-related chronic diarrhea: a crossover, randomized trial. Gastroenterology. 1999; 117 794-797
67 Peralta S, Cottone C, Doveri T et al. Small intestine bacterial overgrowth and irritable bowel syndrome-related symptoms: experience with Rifaximin. World J Gastroenterol. 2009; 15 2628-2631
68 Husebye E. The pathogenesis of gastrointestinal bacterial overgrowth. Chemotherapy. 2005; 51 (Suppl 1) 1-22
69 Gasbarrini A, Lauritano E C, Gabrielli M et al. Small intestinal bacterial overgrowth: diagnosis and treatment. Dig Dis. 2007; 25 237-240
70 Lauritano E C, Gabrielli M, Lupascu A et al. Rifaximin dose-finding study for the treatment of small intestinal bacterial overgrowth. Aliment Pharmacol Ther. 2005; 22 31-35
71 Esposito I, De L A, Di G G et al. Breath test for differential diagnosis between small intestinal bacterial overgrowth and irritable bowel disease: an observation on non-absorbable antibiotics. World J Gastroenterol. 2007; 13 6016-6021
72 Cuoco L, Salvagnini M. Small intestine bacterial overgrowth in irritable bowel syndrome: a retrospective study with rifaximin. Minerva Gastroenterol Dietol. 2006; 52 89-95
73 Majewski M, Sostarich S, Foran P et al. Is rifaximin effective treatment for small intestinal bacterial overgrowth? [ACG abstract 293]. Am J Gastroenterol. 2006; 101 (Suppl) S141
74 Scarpellini E, Gabrielli M, Lauritano C E et al. High dosage rifaximin for the treatment of small intestinal bacterial overgrowth. Aliment Pharmacol Ther. 2007; 25 781-786
75 Lauritano E C, Gabrielli M, Scarpellini E et al. Antibiotic therapy in small intestinal bacterial overgrowth: rifaximin versus metronidazole. Eur Rev Med Pharmacol Sci. 2009; 13 111-116
76 Di Stefano M, Malservisi S, Veneto G et al. Rifaximin versus chlortetracycline in the short-term treatment of small intestinal bacterial overgrowth. Aliment Pharmacol Ther. 2000; 14 551-556
77 Pimentel M, Park S, Mirocha J et al. The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial. Ann Intern Med. 2006; 145 557-563
78 Pimentel M. Review of rifaximin as treatment for SIBO and IBS. Expert Opin Investig Drugs. 2009; 18 349-358
79 Colecchia A, Sandri L, Capodicasa S et al. Diverticular disease of the colon: new perspectives in symptom development and treatment. World J Gastroenterol. 2003; 9 1385-1389
80 Papi C, Koch M, Capurso L. Management of diverticular disease: is there room for rifaximin?. Chemotherapy. 2005; 51 (Suppl 1) 110-114
81 Papi C, Ciaco A, Koch M et al. Efficacy of rifaximin on symptoms of uncomplicated diverticular disease of the colon. A pilot multicentre open trial. Diverticular Disease Study Group. Ital J Gastroenterol. 1992; 24 452-456
82 Latella G, Pimpo M T, Sottili S et al. Rifaximin improves symptoms of acquired uncomplicated diverticular disease of the colon. Int J Colorectal Dis. 2003; 18 55-62
83 Papi C, Ciaco A, Koch M et al. Efficacy of rifaximin in the treatment of symptomatic diverticular disease of the colon. A multicentre double-blind placebo-controlled trial. Aliment Pharmacol Ther. 1995; 9 33-39
84 Colecchia A, Vestito A, Pasqui F et al. Efficacy of long term cyclic administration of the poorly absorbed antibiotic Rifaximin in symptomatic, uncomplicated colonic diverticular disease. World J Gastroenterol. 2007; 13 264-269
85 Di Mario F, Aragona G, Leandro G et al. Efficacy of mesalazine in the treatment of symptomatic diverticular disease. Dig Dis Sci. 2005; 50 581-586
86 Comparato G, Fanigliulo L, Aragona G et al. Quality of life in uncomplicated symptomatic diverticular disease: is it another good reason for treatment?. Dig Dis. 2007; 25 252-259
87 Comparato G, Fanigliulo L, Cavallaro L G et al. Prevention of complications and symptomatic recurrences in diverticular disease with mesalazine: a 12-month follow-up. Dig Dis Sci. 2007; 52 2934-2941
88 Tursi A, Brandimarte G, Daffina R. Long-term treatment with mesalazine and rifaximin versus rifaximin alone for patients with recurrent attacks of acute diverticulitis of colon. Dig Liver Dis. 2002; 34 510-515
89 D’Inca R, Pomerri F, Vettorato M G et al. Interaction between rifaximin and dietary fibre in patients with diverticular disease. Aliment Pharmacol Ther. 2007; 25 771-779
90 Tursi A, Brandimarte G, Giorgetti G M et al. Assessment of small intestinal bacterial overgrowth in uncomplicated acute diverticulitis of the colon. World J Gastroenterol. 2005; 11 2773-2776
91 Gionchetti P, Rizzello F, Morselli C et al. Management of inflammatory bowel disease: does rifaximin offer any promise?. Chemotherapy. 2005; 51 (Suppl 1) 96-102
92 Lukas M, Konecny M, Zboril V. Rifaximin in patients with mild to moderate activity of ulcerative colitis: An open label study. Gastroenterology. 2002; 122 (Suppl 1) A434
93 Guslandi M, Giollo M, Testoni P A. Corticosteroid-sparing effect of rifaximin, a nonabsorbable oral antibiotic, in active ulcerative colitis: Preliminary clinical experience. Curr Ther Res. 2004; 65 292-296
94 Gionchetti P, Rizzello F, Venturi A et al. Antibiotic combination therapy in patients with chronic, treatment-resistant pouchitis. Aliment Pharmacol Ther. 1999; 13 713-718
95 Isaacs K L, Sandler R S, Abreu M et al. Rifaximin for the treatment of active pouchitis: a randomized, double-blind, placebo-controlled pilot study. Inflamm Bowel Dis. 2007; 13 1250-1255
96 Shen B, Remzi F H, Lopez A R et al. Rifaximin for maintenance therapy in antibiotic-dependent pouchitis. BMC Gastroenterol. 2008; 8 26
97 Campieri M, Rizzello F, Venturi A et al. Combination of antibiotic and probiotic treatment is efficacious in prophylaxis of post-operative recurrence of Crohn’s disease: a randomised controlled study vs mesalazine [Abstract]. Gastroenterology. 2000; 118 A781
98 Shafran I, Burgunder P. Rifaximin for the treatment of newly diagnosed Crohn’s disease: a case series. Am J Gastroenterol. 2008; 103 2158-2160

Prof. Dr. Thomas Rabenstein

Innere Medizin und Gastroenterologie, Diakonissen-Stiftungs-Krankenhaus Speyer

Hilgradstraße 26

78346 Speyer

Telefon: ++ 49/62 32/22 18 83

Fax: ++ 49/62 32/22 18 58

eMail: thomas.rabenstein@diakonissen.de